Efficacy of post‐induction therapy for high‐risk neuroblastoma patients with end‐induction residual disease
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34263
Abstract: High‐risk neuroblastoma patients with end‐induction residual disease commonly receive post‐induction therapy in an effort to increase survival by improving the response before autologous stem cell transplantation (ASCT). The authors conducted a multicenter, retrospective study to… read more here.
Keywords: end induction; patients end; risk neuroblastoma; high risk ... See more keywords